Control of widespread hypertrophic lupus erythematosus with T-Cell-directed biologic efalizumab

Dermatology

Volumn 220, Issue 3, 2010, Pages 249-253

  Navarini, Alexander A ^a   Kerl, Katrin ^a   F Rench, Lars E ^a   Trüeb, Ralph M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD4; Efalizumab; Hypertrophic lupus erythematosus; T cells

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; EFALIZUMAB; HYDROXYCHLOROQUINE; ISOTRETINOIN; KERATOLYTIC AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARM; ARTHRALGIA; ARTICLE; BASEMENT MEMBRANE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CRYOTHERAPY; DERMATITIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIDERMIS HYPERPLASIA; ERYTHEMA; FACE; FOLLOW UP; HUMAN; HYPERKERATOSIS; HYPERTROPHIC SKIN DISEASE; LYMPHOCYTIC INFILTRATION; MALE; MINIMAL RESIDUAL DISEASE; PAINTER; PRIORITY JOURNAL; RECURRENT DISEASE; SCAR FORMATION; SKIN BIOPSY; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; WOUND HEALING;

ADULT; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERPLASIA; ISOTRETINOIN; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; PREDNISONE; TREATMENT OUTCOME;

EID: 77951879472     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277614     Document Type: Article

References (41)

1. Kohchiyama A, Oka D, Ueki H: T cell subsets in lesions of systemic and discoid lupus erythematosus. J Cutan Pathol 1985; 12: 493-499.
2. Synkowski DR, Provost TT: Characterization of the inflammatory infiltrate in lupus erythematosus lesions using monoclonal antibodies. J Rheumatol 1983; 10: 920-924.
3. Usmani N, Goodfield M: Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007; 143: 873-877.
4. Pugashetti R, Koo J: Efalizumab discontinuation: a practical strategy. J Dermatolog Treat 2009; 20: 132-136.
5. Bechet PE: Lupus erythematosus hypertrophicus et profundus. Arch Dermatol Syph 1942; 45: 33-39.
6. Otani A: Lupus erythematosus hypertrophicus et profundus. Br J Dermatol 1977; 96: 75-78.
7. Vinciullo C: Hypertrophic lupus erythematosus: differentiation from squamous cell carcinoma. Australas J Dermatol 1986; 27: 76-82.
8. Uitto J, Santa Cruz DJ, Eisen AZ, Leone P: Verrucous lesion in patients with discoid lupus erythematosus: clinical, histopathological and immunofluorescence studies. Br J Dermatol 1978; 98: 507-520.
9. Santa Cruz DJ, Uitto J, Eisen AZ, Prioleau PG: Verrucous lupus erythematosus: ultrastructural studies on a distinct variant of chronic discoid lupus erythematosus. J Am Acad Dermatol 1983; 9: 82-90.
10. Romero RW, Nesbitt LT Jr, Reed RJ: Unusual variant of lupus erythematosus or lichen planus: clinical, histopathologic, and immunofluorescent studies. Arch Dermatol 1977; 113: 741-748.
11. Perniciaro C, Randle HW, Perry HO: Hypertrophic discoid lupus erythematosus resembling squamous cell carcinoma. Dermatol Surg 1995; 21: 255-257.
12. Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, Macdonald TT, Chimenti S, Pallone F, Costanzo A, Monteleone G: Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009; 15: 1013-1015.
13. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W: Interleukin-22, a T H 17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-651.
14. Monteleone G, Pallone F, Macdonald TT: Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 2009; 30: 441-447.
15. Ettinger R, Kuchen S, Lipsky PE: The role of IL-21 in regulating B cell function in health and disease. Immunol Rev 2008; 223: 60-86.
16. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K: IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178: 3822-3830.
17. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, Ziegler J, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Alarcon GS, Vila LM, Alarcon-Riquelme ME, James JA, Gilkeson GS, Jacob CO, Moser KL, Gaffney PM, Vyse TJ, Nath SK, Lipsky P, Harley JB, Sawalha AH: A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2402-2407.
18. Allard EL, Hardy MP, Leignadier J, Marquis M, Rooney J, Lehoux D, Labrecque N: Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol 2007; 37: 3069-3077.
19. Cheng F, Guo Z, Xu H, Yan D, Li Q: Decreased plasma IL-22 levels, but not increased IL-17 and IL-23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 604-606.
20. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA: Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29: 247-256.
21. Stephansson E, Ros AM: Expression of intercellular adhesion molecule-1 (ICAM-1) and OKM5 in UVA-and UVB-induced lesions in patients with lupus erythematosus and polymorphous light eruption. Arch Dermatol Res 1993; 285: 328-333.
22. Wenzel J, Uerlich M, Wörrenkämper E, Freutel S, Bieber T, Tüting T: Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005; 153: 1011-1015.
23. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
24. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70: 562-569.
25. von Wussow P, Jakschies D, Hartung K, Deicher H: Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988; 8: 225-230.
26. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, Mellman I, Schröder JM, Liu YJ, Gilliet M: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
27. Båve U, Magnusson M, Eloranta ML, Perers A, Alm GV, Rönnblom L: Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-3302.
28. Vallin H, Perers A, Alm GV, Rönnblom L: Anti-double-stranded-DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-6313.
29. Wenzel J, Wörrenkämper E, Freutel S, Henze S, Haller O, Bieber T, Tüting T: Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005; 205: 435-442.
30. Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA: The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br J Dermatol 2004; 150: 693-700.
31. Ruzicka T, Meurer M, Bieber T: Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 1988; 124: 897-902.
32. Callen JP: Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus 1997; 6: 203-208.
33. Dooley MA, Ginzler EM: Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 2006; 32: 91-102, ix.
34. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmüller G: Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cMT412. J Am Acad Dermatol 1996; 34: 244-252.
35. Booken N, Schumann T, Fuchslocher M, Goerdt S, Goebeler M: Successful therapy of discoid lupus erythematosus with efalizumab (in German). Hautarzt 2009, E-pub ahead of print.
36. Rodríguez-Lojo R, Paradela S, Martínez-Gómez W, Fernández-Torres R, Fonseca E: Refractory discoid lupus erythematosus: response to efalizumab. J Eur Acad Dermatol Venereol 2009; 23: 1203-1205.
37. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG: Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102: 19057-19062.
38. Berthelot C, Nash J, Duvic M: Coexistent psoriasis and lupus erythematosus treated with alefacept. Am J Clin Dermatol 2007; 8: 47-50.
39. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
40. 1 integrin. Nature 1992; 356: 63-66.
41. Tieng AT, Peeva E: B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38: 218-227.